Eli Lilly and Co

NYSE:LLYUnited States

Jul 3, 2024

Show headlines and story abstract

• DJ Rival To Eli Lilly's Alzheimer's Drug Seen As Potentially Safer -- Market Talk, from 10:17AM ET on Wednesday Jul 03, 2024 by Dow Jones

  10:17AM ET on Wednesday Jul 03, 2024 by Dow Jones
  Companies Mentioned: LLY, BIIB
  
  1017 ET - Eli Lilly's new Alzheimer's drug Kisunla, which was approved by the FDA on Tuesday, may not have as strong of a safety profile as Eisai and Biogen's Leqembi, Third Bridge analyst Lee Brown says in a note. Specialists at his firm believe the FDA-approved Leqembi, introduced last year, may have a superior safety profile given that it uses a slightly different mechanism of action, Brown says. Leqembi targets an early intermediate amyloid structure, while Kisunla targets large aggregated accumulations of amyloid beta, and the difference in targeting may allow for consistently lower Amyloid Related Imaging Abnormalities risk with Leqembi, the analyst says. (dean.seal@wsj.com)
  

• DJ Eli Lilly Is Maintained at Outperform by BMO Capital, from 9:07AM ET on Wednesday Jul 03, 2024 by Dow Jones

  9:07AM ET on Wednesday Jul 03, 2024 by Dow Jones
  Companies Mentioned: LLY
  
  Ratings actions from Benzinga: https://www.benzinga.com/quote/LLY/analyst-ratings
  
  (END) Dow Jones Newswires
  
  July 03, 2024 09:07 ET (13:07 GMT)
  

• Stocks Edge Up Pre-Bell Ahead of Several Key Economic Reports; Asia, Europe Rise, from 7:09AM ET on Wednesday Jul 03, 2024 by MT Newswires

  7:09AM ET on Wednesday Jul 03, 2024 by MT Newswires
  Companies Mentioned: LLY, TSLA, STZ, PARA
  07:09 AM EDT, 07/03/2024 (MT Newswires) -- US equity markets were pointing marginally higher in Wednesday's premarket activity as traders await the minutes of the Federal Reserve's latest policy meeting, as well as the release of several key economi...